Public Health In 2012: A Busy Crossroads Of Partnership, Innovation, And Trade 17/02/2012 by Rachel Marusak Hermann, Intellectual Property Watch Leave a Comment From advancing public-private partnerships and increasing international collaboration to promoting innovation in neglected therapy areas and developing new research and development models, policymakers have set a steady pace as they advance the 2012 global health agenda.
In 2012: Are Biotech, Ethics And Biodiversity Friends or Foes? 08/02/2012 by Catherine Saez, Intellectual Property Watch Leave a Comment With food demand and prices rising as the world crosses the threshold of 7 billion people, the need to find new medicines, concerns about the shrinking biodiversity and the effects of climate change may designate biotechnologies as the main response. Opinions differ on the way to address those issues, in particular about intellectual property rights attached to biotechnologies. Legislative questions are being discussed on both sides of the Atlantic around the scope of patentability, and intellectual property rights on plants, seeds, molecules or methods, as well as exemptions that some think should be applied. The year ahead will see some decisions that might impact the biotechnology industry both in the United States and in Europe.
Will The Old Music Industry Giants Be Exchanged For New Ones? 02/02/2012 by Monika Ermert for Intellectual Property Watch Leave a Comment CANNES, FRANCE–The red carpets were still there at the Midem, the world’s largest music fair, but they have become shorter. The industry shattered over the years by the decline in physical sales and fighting fiercely against digital piracy this year praised the revenue from digital sources which have overtaken physical sales in some countries. But it remains to be seen – can the old giants partner with the new, digital platform giants, and survive?
SOPA, Piracy, Pharmaceuticals May Dominate US IP Policy Discussions In 2012 23/01/2012 by Liza Porteus Viana, Intellectual Property Watch 2 Comments Online piracy, patent reform and intellectual property issues relating to pharmaceuticals are among the top legislative and regulatory priorities for many stakeholder groups in the United States this year, but given that 2012 is an election year, chances are slim that Congress will push through anything that isn’t a top priority or that could cause too much partisan rancour.
Occupy IP: New Economy Businesses Clash With Old 20/01/2012 by Intellectual Property Watch 2 Comments It may be too much, too late for content providers finally trying to tame the internet, and a fresh approach is needed, writes Bruce Berman.
Year Ahead: Busy Copyright Schedule As Europe Seeks Economic Recovery 19/01/2012 by Dugie Standeford for Intellectual Property Watch Leave a Comment With European hopes for economic recovery pinned in large part on a more vibrant digital single market, 2012 will likely see a flurry of intellectual property-related legislative activities. Much of it centres on copyright, but the year may also bring movement on a unified European patent and changes in trademark law.
Change Of Year Brings Changes In IP Community 16/01/2012 by William New, Intellectual Property Watch Leave a Comment The turning of a new year offers the opportunity to catch up on a range of recent personnel changes in the international IP policy and legal communities.
The Year Ahead 2012: Top IP Legal Issues In The United States 13/01/2012 by Steven Seidenberg for Intellectual Property Watch 2 Comments This year could bring major changes in US intellectual property law. Congress and the nation’s courts will be confronting a variety of issues that have broad ramifications for copyrights, trademarks and patents. Here are some of the top developments to watch in 2012.
Johnson & Johnson Denies Patent Pool Licences For HIV Medicines For The Poor 12/01/2012 by William New, Intellectual Property Watch Leave a Comment In a move public health advocates say is likely to bring negative consequences for low-income patients with HIV and AIDS, as well as negative publicity for the company, Johnson & Johnson recently announced that it would not enter into negotiations with the Medicines Patent Pool for voluntary licences that would allow several of key treatments to be made in more affordable generic form in developing countries.
US Competitiveness Report Shows Struggle With Balance Of IP And Access 09/01/2012 by William New, Intellectual Property Watch 1 Comment A new report from the United States Department of Commerce on competitiveness and innovation details the US need to boost innovation in order to compete globally and grow the economy. But while it stresses the need for strong intellectual property rights enforcement to create high-priced monopolies as an incentive for innovation, it also acknowledges that access to inexpensive technology and ideas is key to innovation and entrepreneurship. Furthermore, it shows that the rise in IP rights in recent years has been accompanied by a drop in innovation.